8 Includes any other perquisites, benefits in-kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization and reimbursement of additional taxes arising from international business travel).

filing / Feb 4, 2026 / receipt

4 Includes any other perquisites, benefits in-kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization and reimbursement of additional taxes arising from international business travel).

filing / Feb 4, 2026 / receipt

• Discussed longer-term succession planning and appointed the successor of the Company’s CFO • Discussed and reviewed the annual Board self-evaluation • Participated with the ECN in town halls for Novartis employees in different locations around the world Meetings Number of meetings held 12 Number of members 12 Approximate average duration (hours) 4:55 Meeting attendance 96% The Board met 12 t

filing / Feb 4, 2026 / receipt

There is also an additional risk that aggressive monetary and fiscal policies by governments and central banks to curb inflation may prompt market-specific recessions and raise the cost-of-living, further putting pressure on pricing and cost containment for the pharmaceutical industry.

filing / Feb 4, 2026 / receipt

The following items that exceed a threshold of USD 25 million are also excluded: integration- and divestment-related income and expenses, divestment gains and losses, restructuring charges/releases and related items, legal-related items, impairments of property, plant and equipment, software, and financial assets, and income and expense items that management deems exceptional and that are or are expected to accumulat

filing / Feb 4, 2026 / receipt

While the FDA’s review of marketing applications and other activities for new drugs and biologics is largely funded through the user fee program established under the Prescription Drug User Fee Act, it remains unclear how any reduction in force and budget cuts will impact this program and the ability of the FDA to provide guidance and review our product candidates in a timely manner.

filing / Feb 4, 2026 / receipt

S. Moroney | Vice-Chair | 12/12 | 5/5 | 5/5

filing / Feb 4, 2026 / receipt

P. Bula | Lead Independent Director | 12/12 | 5/5 | 3/3

filing / Feb 4, 2026 / receipt

N. Andrews | Member | 11/12 | 3/3 | 5/5

filing / Feb 4, 2026 / receipt

T. Buechner | Member | 12/12 | 7/7 | 3/3

filing / Feb 4, 2026 / receipt

E. Doherty | Member | 11/12 | 7/7 | 3/3

filing / Feb 4, 2026 / receipt

B. Heller | Member | 10/12 | 6/7 | 5/5 | 3/3

filing / Feb 4, 2026 / receipt